Medicxi Closes a New €400m Fund (Medicxi III) to Power the Next Wave of Biopharma Entrepreneurs and Drug Hunters
ApcinteX Starts Clinical Trial of Novel Haemophilia Drug
Divide & Conquer, Developing New Class of Cancer Therapeutics to Disrupt Cell-to-Cell Communication, Emerges from Stealth as New Paper by Co-Founder is Published in Nature
Evotec and venture capital consortium form "Breakpoint Therapeutics GmbH"
All rights reserved © Medicxi, 2019